Agilent Is Down 9% After 1,800 Days. What History Says Now

Agilent Recovered From Its Yellow Zone After 1,798 Days

Agilent Technologies, Inc. (A) is now down -8.7% from its all-time high as of August 21, 2026, having just exited the yellow zone after 1,798 days. The Drawdown Severity Score™ has improved to 1.7, which indicates a Slightly Elevated severity level and places the stock in the green zone. In 13 comparable prior recoveries where the stock dropped 5% or more, Agilent took an average of 592 days to recover.

Earnings Catalyst Drives Agilent's Recovery to the Green Zone

The primary driver behind Agilent's transition out of the yellow zone is its recent financial performance and updated outlook. According to simplywall.st, Agilent shares experienced a 7.0% increase following a second-quarter earnings beat and an upward revision to its full-year 2026 guidance. This positive financial update provided the fundamental momentum necessary to push the stock past key resistance levels and reduce its overall drawdown severity.

Additionally, Agilent recently achieved a new 52-week high of $160.36, as reported by Investing.com. This price milestone confirms that buyers are returning to the asset, helping to reverse some of the long-term downward pressure. Investors are also looking forward to an upcoming catalyst scheduled for August 26, 2026, according to 24/7 Wall St., which could further influence the stock's short-term trajectory.

The combination of strong earnings execution and raised guidance has fundamentally shifted investor sentiment. This shift has allowed the stock to break out of its previous consolidation range, demonstrating that solid operational performance remains a powerful catalyst for overcoming extended drawdowns.

Analyzing the 1,798-Day Drawdown Journey

Agilent's current drawdown has been an exceptionally long journey, lasting 1,798 days since the stock reached its all-time high of $174.07. As of August 21, 2026, the stock trades at $158.93, representing an -8.7% decline from that peak. This multi-year period has been characterized by consolidation, as the broader life sciences and diagnostics sectors adjusted to normalized spending levels following the pandemic-era surge.

During this 1,798-day period, the stock repeatedly tested lower levels, occasionally entering the yellow zone as market uncertainty persisted. The yellow zone indicates that a drawdown's depth and duration have exceeded typical historical baselines, signaling elevated risk for investors. The recent shift back to the green zone suggests that the worst of this multi-year consolidation phase may be stabilizing.

This long-term decline has tested the patience of market participants, as drawdown duration fatigue often leads to capital outflows. However, the transition back to the green zone indicates that the selling pressure has finally exhausted itself. This structural shift is a key technical milestone for the stock's long-term recovery path.

Recovery By the Numbers: Severity and Price Analysis

A closer look at the data reveals that the current Drawdown Severity Score™ stands at 1.7, which corresponds to a Slightly Elevated risk level. This score is calculated by comparing the depth and duration of the current pullback against Agilent's entire trading history. The improvement to 1.7 represents a meaningful decrease in risk from the previous yellow zone status, indicating that the stock's price action is returning to a more normalized state.

To fully reclaim its all-time high of $174.07, Agilent must close a remaining gap of $15.14 per share, which represents a further 9.53% gain from its current price of $158.93. While the stock remains below its peak, the current -8.7% drawdown is relatively mild in terms of absolute depth, even though the time spent in this drawdown has been extraordinarily long. This divergence between mild depth and extreme duration is a unique characteristic of Agilent's current market cycle.

Our proprietary severity score helps investors contextualize these movements by stripping away short-term market noise. A score of 1.7 shows that while the stock remains below its historical peak, the current drawdown is well within historical tolerances. This suggests that the stock is no longer exhibiting high-risk distress signals.

Historical Context: Past Drawdowns and Recovery Timelines

To put the current 1,798-day drawdown into perspective, we can examine Agilent's historical drawdown database. Over its trading history, Agilent has experienced 43 total historical drawdown events. On average, these drawdowns reached a maximum depth of -5.6% and lasted for 183 days before the stock recovered to a new high.

When we look specifically at comparable pullbacks of 5% or more, Agilent has experienced 13 such occurrences. These larger drawdowns had an average duration of 592 days. Comparing these historical benchmarks to the current cycle highlights just how unprecedented the current 1,798-day period is.

The table below contrasts the current drawdown metrics with Agilent's historical averages:

This comparison shows that while the current depth of -8.7% is only slightly worse than the historical average of -5.6%, the duration of 1,798 days is nearly ten times longer than the average drawdown. Even when compared to the 13 historical drops of 5% or more, which averaged 592 days, the current cycle is more than three times longer. This suggests that the stock has undergone an unusually prolonged period of base-building and consolidation.

Valuation Context: Contrasting Price and Multiples

As of 2026-08-21, Agilent's price drawdown of -8.7% contrasts with its valuation multiples, which remain elevated relative to the company's own historical footprint. The price-to-sales (P/S) ratio stands at 6.1, placing it in the 88th percentile of its own daily P/S record since 2006-08-21, well above its historical median of 3.6. Similarly, the EV-to-EBITDA ratio is 25.1, positioning it in the 85th percentile of its own daily EV/EBITDA record since 2006-08-21, compared to a historical median of 18.7. This indicates that while the stock price remains below its all-time high, the underlying valuation multiples are sitting near the upper end of their historical ranges.

Is the Sell-Off Over? Evaluating Risk and Retest Probabilities

With the Drawdown Severity Score™ improving to 1.7, the immediate risk of a deeper sell-off has decreased, but investors must still monitor potential headwinds. According to DirectorsTalk Interviews, Wall Street analysts maintain a consensus target price that implies a 7.79% upside from current levels. This target suggests that analysts expect the stock to continue its steady climb back toward its historical peak.

However, the upcoming catalyst on August 26, 2026, noted by 24/7 Wall St., represents a key event that could introduce fresh volatility. If the news is received positively, it could propel the stock closer to its all-time high. Conversely, if the market is disappointed, the stock could face a retest of its previous support levels, potentially pushing the severity score back into the yellow zone.

Furthermore, broader macroeconomic indicators and laboratory spending trends will continue to play a critical role. While the company's upgraded guidance is a strong positive signal, any broader slowdown in capital expenditure within the pharmaceutical and biotechnology sectors could slow the pace of recovery. Investors should watch whether the stock can maintain its position above the key support levels established during this recent rebound.

Key Levels: Technical and Severity Thresholds to Monitor

To track Agilent's ongoing recovery, several technical and severity thresholds should be closely monitored. First, the 1.7 Drawdown Severity Score™ must remain below the 2.0 threshold to stay within the lower-risk green zone. A rise above 2.0 would indicate that the drawdown is worsening or extending in a way that increases overall risk.

In terms of price levels, the recent 52-week high of $160.36, reported by Investing.com, serves as an immediate resistance level. A sustained break above this price would signal continued bullish momentum. On the downside, the current price of $158.93 and the levels established prior to the Q2 earnings beat will act as key support areas during any market pullbacks.

By keeping a close eye on these metrics, investors can assess whether Agilent is truly on a sustainable path to reclaiming its all-time high or if it remains vulnerable to another period of consolidation. Monitoring these specific data points provides the necessary context to make informed observations without relying on market speculation.